Hypertriglyceridemia Therapeutics Market to Reach US$ 12 Billion by 2027 - Coherent Market Insights

Global Hypertriglyceridemia Therapeutics Market, by Type (Primary and Secondary), by Drug Class (Statins, Fibrates, Niacin, Omega-3 Fatty Acids, and HMG-CoA Reductase inhibitors), by Distribution Channel (Online Pharmacy, Retail Pharmacy, Hospital Pharmacy, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is expected to be valued at US$ 9,716.6 million in 2020 and is estimated to exhibit a CAGR of 4.09% during the forecast period (2020-2027), as highlighted in a new report published by Coherent Market Insights.

Players in the market are focused on research & development and drug approvals for the treatment of hypertriglyceridemia. Companies having drugs in phase 3 trials include Mochida Pharmaceutical Company, Ltd., Acasti Pharma Inc., and EMS. 

Besides, in March 2019, Arrowhead Pharmaceuticals initiated a phase I clinical trial of ‘ARO-APOC3’ for hypertriglyceridemia treatment. ARO-APOC3 is the second cardiometabolic candidate of Arrowhead that has entered clinical trials, followed by ARO-ANG3 for dyslipidemias and metabolic diseases treatment.

In July 2019, Sun Pharma launched Rosuvastatin in the U.S. for people who have difficulty swallowing. Rosuvastatin or Ezallor Sprinkle capsules are indicated as an adjunct to the diet of adult patients with hypertriglyceridemia. It is also indicated as an adjunct to diet for the treatment of adult patients with type III hyperlipoproteinemia and to other lipid-lowering treatments.

Global Hypertriglyceridemia Therapeutics Market - Impact of Coronavirus (Covid-19) Pandemic

The COVID-19 outbreak has affected the hypertriglyceridemia therapeutics market growth. The COVID-19 patients are at risk for developing hypertriglyceridemia, majorly owing to systemic inflammation. Thus, ideally keeping the propofol dosages can help to maintain sedation and prevent conditions such as hypertriglyceridemia. It is becoming difficult for researchers and key industry players to conduct clinical trials during this pandemic crisis. However, many market players such as Eli Lilly and Company, and Pfizer Inc. are investing in research and development to produce novel drugs for hypertriglyceridemia.

Browse 26 Market Data Tables and 28 Figures spread through 166 Pages and in-depth TOC on Hypertriglyceridemia Therapeutics Market, By Type (Primary and Secondary), By Drug Class (Statins, Fibrates, Niacin, Omega-3 Fatty Acids, and HMG-CoA Reductase inhibitors), By Distribution Channel (Online Pharmacy, Retail Pharmacy, Hospital Pharmacy, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), Forecast to 2027”

To know the latest trends and insights related to the Global Hypertriglyceridemia Therapeutics Market, click the link below:

https://www.coherentmarketinsights.com/market-insight/hypertriglyceridemia-therapeutics-market-4020

The rising prevalence of cardiovascular diseases and drug approvals for the treatment of hypertriglyceridemia are expected to contribute to the growth of the Asia Pacific hypertriglyceridemia therapeutics market. As per the Department of Nutrition and Health Sciences, 2019, cardiac problems accounts for seven out of every 10 deaths in Asian countries.

Key Takeaways of the Global Hypertriglyceridemia Therapeutics Market:

• The global hypertriglyceridemia therapeutics market is expected to exhibit a CAGR of 4.09% during the forecast period (2020-2027) owing to investments in research & development and product approvals.
• Among type, the primary hypertriglyceridemia segment is likely to account for the largest revenue share by 2027 owing to the rising incidence of obesity and adoption of sedentary lifestyle. For instance, according to the Centers for Disease Control and Prevention, the prevalence of obesity was about 42.4% in the U.S. from 2017 to 2018.
• Major players operating in the global hypertriglyceridemia therapeutics market are Sanofi, Novo Nordisk A/S, GlaxoSmithKline Plc, Biocon, Oramed Pharmaceuticals, Inc, Tonghua Dongbao Pharmaceutical Co., Ltd., Merck & Co., Inc., Eli Lilly and Company, Julphar, Aurobindo Pharma, Bristol-Myers Squibb Company, Adocia, Pfizer Inc., Hikma Pharmaceutical PLC, AbbVie Inc., Lupin Ltd., Wockhardt, Glenmark, Accord Healthcare, Amneal pharmaceutical LLC, and Zydus Pharmaceuticals Inc.